Synvista's Alagebrium, Potential for use in Treating Diabetes-Related Gastrointestinal Complications

Oct. 25 , 2007 - Synvista Therapeutics, Inc. (AMEX: SYI) announced the publication of preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced glycated end-products (AGEs) and restore neuronal nitric oxide synthase (nNOS) activity in rats with diabetes... Synvista's Press Release -